Condition: HIV-1-infection · Sponsor: Gilead Sciences
The goal of this clinical study is to learn more about the study drug, lenacapavir (LEN). The study will assess the safety, tolerability, and efficacy of long-acting LEN when combined with other medicines in adolescents and children living with HIV-1 who weigh at least 35 kg and have been treated before for HIV-1. The study will also see how easy it is for participants to take LEN as injection or an oral pill. The primary objectives are to evaluate the pharmacokinetics and safety of LEN in combination with optimized background regimen (OBR) in TE pediatric participants with HIV-1.
This description comes directly from the study's public registry record.
Gilead Clinical Study Information Center · 1-833-445-3230 (GILEAD-0) · GileadClinicalTrials@gilead.com
Always discuss trial participation with your own doctor first.
| Grady Health System, Ponce De Leon Center | Atlanta, Georgia, United States | Recruiting |
| FAMCRU | Cape Town, South Africa | Recruiting |
| CRISMO Research Centre | Germiston, South Africa | Recruiting |
| Wits RHI Shandukani Research Centre CRS | Johannesburg, South Africa | Recruiting |
| Rahima Moosa Mother and Child Hospital | Johannesburg, South Africa | Recruiting |
| Clinical Research Institute of South Africa (CRISA) | KwaDukuza, South Africa | Recruiting |
| Durban International Clinical Research Site, Enhancing Care Foundation | KwaZulu - Natal, South Africa | Recruiting |
| Be Part Research Pty (Ltd) | Paarl, South Africa | Recruiting |
| Perinatal HIV Research Unit (PHRU) | Soweto, South Africa | Withdrawn |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06749054